(Reuters) -Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.
The trial, which studied 2.4 milligram dose of semaglutide, showed a statistically significant improvement in the condition called metabolic dysfunction-associated steatotic liver disease.
Novo’s semaglutide is sold as Wegovy for weight loss and Ozempic for diabetes.
(Reporting by Sriparna Roy in Bengaluru; Editing by Arun Koyyur)
Comments